6505-- F-18 Pylarify - Radiopharmaceutical Cincinnati VAMC, 539C65197
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the Cincinnati VAMC, has awarded a contract to PROGENICS PHARMACEUTICALS INC for F-18 Pylarify - Radiopharmaceutical services. This award, valued at $559,351.60, was made on May 7, 2026, under a limited sources justification due to the unique nature of the product.
Scope of Work
This contract provides for approximately 155 doses of Piflufolastat F-18 (PYLARIFY), a radiopharmaceutical essential for the Nuclear Medicine Department at the Cincinnati VAMC. Deliveries will be made on an as-needed basis to support ongoing medical requirements.
Contract & Timeline
- Type: Limited Sources Acquisition (Delivery Order under FSS Contract)
- Awardee: PROGENICS PHARMACEUTICALS INC
- Award Number: 36F79725D0093 36C25026N0531
- Value: $559,351.60
- Period of Performance: May 1, 2026 - April 30, 2027
- Set-Aside: Not applicable (Sole Source Justification)
- Award Date: May 7, 2026
- Published Date: May 8, 2026
Justification & Evaluation
This acquisition was justified as a limited source procurement under GSAR 538.7104-3(b)(1)(ii) because Progenics Pharmaceuticals is the sole manufacturer of Piflufolastat F-18 (PYLARIFY). Market research, including NAICS Code 325412, did not identify other vendors capable of providing this specialized radiopharmaceutical, thus the VA Rule of Two and SBA Rule of Two could not be satisfied. The FDA has approved Progenics Pharmaceuticals as a sole source vendor for this product.
Additional Notes
The Department of Veterans Affairs will conduct annual market research for future procurements of similar agents to identify any comparable products that may become available.